Partner Network

Beyond discovery

Discovery is what we do ourselves. For the rest of the preclinical pipeline we work with selected, internationally accredited contract research organizations — coordinated through a single point of contact.

Preclinical Pharmacology

  • 800+ validated in vivo disease models
  • Tumor, autoimmune, CNS, metabolic, cardiovascular, ocular
  • Rodent, NHP and large animal species

In Vitro Biology & Screening

  • 1,000+ established in vitro assay platforms
  • Enzyme / kinase, GPCR, cell viability, immunology
  • HTS, FACS, biomarker and PD analysis

CMC / API Development

  • Process development from lab to GMP scale
  • Salt screening, polymorph, analytical method validation
  • IND / NDA regulatory dossier support

GLP Toxicology

  • FDA, NMPA, OECD and AAALAC accredited facilities
  • Single and repeat-dose, reproductive, genotoxicity
  • Safety pharmacology and toxicokinetics

Regulated Bioanalysis & ADME

  • GLP-grade bioanalysis for regulatory submission
  • Small and large molecule LC-MS/MS
  • Full ADME panels
  • Immunogenicity (ADA, NAb)

IND Filing Support

  • 500+ successful global IND submissions
  • Dual and triple-nation filings (NMPA, FDA, TGA, EMA)
  • End-to-end package from discovery to IND
PK/PD studies are run in-house — see Functional Evaluation. Partners are engaged where GLP certification or a regulatory dossier is required.
How partners are selected. On GLP certification, regulatory track record, and alignment with our quality standards. Partner identities are kept confidential under mutual agreement, and we are happy to discuss capability specifics under NDA.

Planning beyond discovery?

Tell us where the program is heading and we will map which capabilities you will need and when.

Get in touch